Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.20.2
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Licensing and other arrangements            
Revenue from contracts with customers   $ 53 $ 625 $ 553 $ 8,651  
Janssen Biotech Inc. | License Agreement            
Licensing and other arrangements            
One-time payment $ 2,500          
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events $ 3,000          
Percentage of royalty on worldwide net sales of each product upon commercialization 0.75%          
Revenue from contracts with customers       0   $ 2,500
Contract assets   0   0    
Contract liabilities   0   0    
Capitalized contract costs   $ 0   $ 0